Scheen AJ. GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?. Ann Endocrinol (Paris). 2013;74:515-522.GLP-1 receptor agonists or DPP4 inhibitors;How to guide the clinician?. Scheen AJ. Annales d Endocrinologie . 2013...
How do GLP-1 agonists help with weight loss? They may make you feel less hungry by keeping any food you eat in your GI tract for longer. This makes it take longer for you to feel hungry again after a meal, so it’s easier to eat less. They may also send signals to your brain ...
Coincident with advances in biotherapeutic engineering, these studies inspired drug discovery campaigns on GLP-1 over the subsequent two decades that delivered GLP-1 receptor agonists (GLP-1RAs) for treating T2DM. These became the first glucose-lowering medications to reduce bodyweight, and some ...
These medications have a similar effect to the natural hormones, but are resistant to being broken down by DPP-4. These drugs can help to lower blood glucose and may also aid weight loss and help prevent heart disease. Examples of GLP-1 receptor agonists include Trulicity, Byetta, and ...
Otherwise known as Glucagon-like Peptide 1 receptor agonists, Ozempic, Wegovy and other GLP-1s have created a lot of buzz in the media lately after being approved for weight loss. For good reason! This class of diabetes medications can help you lose weight and lower blood sugar. Even so,...
Scheen AJ. GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? Ann Endocrinol (Paris) 2013; 74(5-6): 515-522. [PubMed].Scheen AJ. GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? Ann Endocrinol (Paris). 2013;74(5-6):515-522....
Increasing evidence suggests that these agents differ considerably from endogenous GLP‐1 when it comes to their routes of action, although their clinical effects appear to be the same. Given the limitations of the GLP‐1 receptor agonists, could it be useful to develop agents which stimulate GLP...
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes? : Completed and Ongoing Mechanistic Trialsdoi:info:doi/10.1161/ATVBAHA.119.311904Lee, Matthew M.Y.
How to assess kidney outcomes in obese people with substantial weight loss: the case of GLP1- and dual-receptor agonistsdoi:10.1093/ndt/gfae024Rothberg Amy EHerman William HNephrology Dialysis Transplantation